SCHEMBL10025834

SCHEMBL10025834

c1ccc(-c2c3ccccc3c3c4ccc(s4)c4c5ccccc5c(-c5ccccc5)c5ccc(cc54)c4cccc(c4)c4cccc(c4)c4ccc2c3c4)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 10/20 0.44
ESR2 Q92731 8/20 0.44
CYP1A2 P05177 4/20 0.41
ERBB2 P04626 1/20 0.41
FYN P06241 1/20 0.41
MAOA P21397 1/20 0.41
ACHE P22303 1/20 0.41
AHR P35869 1/20 0.41
CYP1B1 Q16678 3/20 0.39
CYP1A1 P04798 2/20 0.39
NQO2 P16083 2/20 0.36
NQO1 P15559 1/20 0.36
ALDH1A1 P00352 2/20 0.36
HSD17B10 Q99714 2/20 0.36
THRB P10828 1/20 0.36
HPGD P15428 1/20 0.36
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
HSD17B1 P14061 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13507025 0.84 ESR1 (0.38) ESR1ESR2CYP1A2CYP1B1CYP1A1
SCHEMBL13507134 0.82 ESR1 (0.39) ESR1ESR2CYP1A2CYP3A4CYP2D6
SCHEMBL17943991 0.81 S1PR5 (0.41) ESR1ESR2CYP1A2CYP3A4CYP2D6
SCHEMBL17945210 0.81 CYP1A1 (0.38) ESR1ESR2CYP1A2FYNAHR
SCHEMBL22217375 0.80 HPRT1 (0.38) ESR1ESR2CYP1A2ERBB2FYN
SCHEMBL19110208 0.80 ESR1 (0.37) ESR1ESR2CYP1A2ALDH1A1HPGD
SCHEMBL17943984 0.80 F9 (0.39) ESR1ESR2CYP1A2FYNAHR
SCHEMBL17944285 0.80 CYP1A1 (0.39) ESR1ESR2CYP1A2FYNAHR
SCHEMBL13507082 0.80 MAPT (0.36) ESR1ESR2MAOAACHEALDH1A1
SCHEMBL25128993 0.79 ESR1 (0.39) ESR1ESR2CYP1A2CYP1B1CYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124249-B2 Derivatives of fused aromatic systems; stability; sublimation stability; easy to purify due to better solubilty; easy reproducibility because do not form isomers MERCK PATENT GMBH (DE) 2012-02-28 US disclosed
US-8124249-B2 Derivatives of fused aromatic systems; stability; sublimation stability; easy to purify due to better solubilty; easy reproducibility because do not form isomers MERCK PATENT GMBH (DE) 2012-02-28 US disclosed
US-20080171225-A1 Novel Materials For Organic Electroluminescent Devices MERCK PATENT GMBH (DE) 2008-07-17 US disclosed
US-20080171225-A1 Novel Materials For Organic Electroluminescent Devices MERCK PATENT GMBH (DE) 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171225-A1 Novel Materials For Organic Electroluminescent Devices OR10J3, EML4, TYR ESR1 201/4885ESR2 515/4885CYP1A2 2355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.